Principal Investigator
Marijo Bilusic
Enrollment Status
Open
Clinical Trial ID
Institutional Protocol #
20231239
Clinical Trial Summary
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA)
and Taxane-based Chemotherapy
Phase
Phase III
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
305-243-2647